CSS
KZR

Cubist Systematic Strategies’s Kezar Life Sciences KZR Stock Holding History

Cubist Systematic Strategies’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-28,969
Closed -$710K – 3665
2023
Q2 		$710K Buy
28,969
+4,555
+19% +$119K ﹤0.01% 2177
2023
Q1 		$764K Buy
24,414
+22,308
+1,059% +$1.29M ﹤0.01% 2397
2022
Q4 		$148K Sell
2,106
-5,316
-72% -$394K ﹤0.01% 3696
2022
Q3 		$639K Sell
7,422
-2,034
-22% -$198K ﹤0.01% 2982
2022
Q2 		$782K Buy
9,456
+8,162
+631% +$720K ﹤0.01% 2678
2022
Q1 		$215K Buy
1,294
+34
+3% +$4.88K ﹤0.01% 3014
2021
Q4 		$211K Buy
+1,260
New +$142K ﹤0.01% 3004
2020
Q3 		– Sell
-1,490
Closed -$77K – 2562
2020
Q2 		$77K Buy
+1,490
New +$75.2K ﹤0.01% 2240
2019
Q2 		– Sell
-418
Closed -$74K – 2523
2019
Q1 		$74K Buy
+418
New +$82.4K ﹤0.01% 2046

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cubist Systematic Strategies's KZR Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of Kezar Life Sciences (KZR) in Q3 2023, closing a stake of 28,969 shares — an estimated $710K sold.

Cubist Systematic Strategies first reported a position in KZR in Q1 2019 and held it in 9 quarters. The position peaked at $782K in Q2 2022. 82 funds tracked by Wall St. Rank hold KZR as of Q3 2023.

  • Cubist Systematic Strategies reported no remaining Kezar Life Sciences position as of Q3 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 28,969 Kezar Life Sciences shares in Q3 2023, an estimated $710K.
  • Cubist Systematic Strategies first reported a position in Kezar Life Sciences in Q1 2019 and held it in 9 quarters.
  • Cubist Systematic Strategies's Kezar Life Sciences position peaked at $782K in Q2 2022.
  • 82 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.